Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
XORTX Therapeutics Inc
V.XRTX
Alternate Symbol(s):
XRTX
Healthcare
XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance...
its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSXV:XRTX)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jun 13, 2022 8:55am
New Press Release - XORTX to Present at BIO International Convention 2022
CALGARY, Alberta, June 13, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce...
read article.
(54)
•••
Richmond
X
View Profile
View Bullboard History
Comment by
Richmond
on Jun 11, 2022 2:11am
RE:After good news there is bad one
You are dead on!!! These mf's are fooling the investors
Lahontan Gold Announces Filing of Santa Fe Technical Report
posted Nov 29, 2024 9:00am by
Lahontan Gold Corp.
-
|
Lahontan Gold is pleased to announce that the Company has filed on SEDAR+ an independent Technical Report and updated Mineral Resource Estimate ("MRE") titled "Santa Fe Project Technical Report," effective October 9, 2024, and dated November 27, 2024, for Lahontan's Santa Fe Mine gold and silver project, Santa Fe District, Mineral County, Nevada. ...read more
(54)
•••
Richmond
X
View Profile
View Bullboard History
Post by
Richmond
on Jun 11, 2022 2:09am
Depressing Share Price
How many more investors can afford to lose, like the ones that saw XORTEX rolled back at $10.00 and now down to $1.00. Really sickening!! Stockhouse Logo Search Companies, etc News Press Releases
...more
(264)
•••
moneywinner1
X
View Profile
View Bullboard History
Post by
moneywinner1
on Jun 08, 2022 10:44am
After good news there is bad one
Is travels are tooo expensive, get davidof to work and show the work not travel to see investors . Are you looking for financing and dilution you mf
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jun 08, 2022 7:00am
New Press Release - XORTX to Present at LD Micro Invitational 2022
CALGARY, Alberta, June 08, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce...
read article.
(264)
•••
moneywinner1
X
View Profile
View Bullboard History
Post by
moneywinner1
on Jun 07, 2022 1:56pm
Xrtx on Nasdaq is up 16% now
Tsx on canafian side has lower volume and only 6% wow you cCsnadians
(264)
•••
moneywinner1
X
View Profile
View Bullboard History
Comment by
moneywinner1
on Jun 07, 2022 1:31pm
RE:On Nasdaq is 10% already
Converted Nasdaq price to Canadian dollar it trades at $2.12 Canadian
(264)
•••
moneywinner1
X
View Profile
View Bullboard History
Post by
moneywinner1
on Jun 07, 2022 12:40pm
On Nasdaq is 10% already
Let's see $2 next trade on Canadian side ,
(264)
•••
moneywinner1
X
View Profile
View Bullboard History
Post by
moneywinner1
on Jun 07, 2022 12:33pm
Price crossed 21 day moving average
This one is $5 back in a week
(264)
•••
moneywinner1
X
View Profile
View Bullboard History
Post by
moneywinner1
on Jun 07, 2022 12:32pm
On Nasdaq is up 7% , tsx trades down 2.5%
Something has to give, I go with Nasdaq trades and like it
(264)
•••
moneywinner1
X
View Profile
View Bullboard History
Post by
moneywinner1
on Jun 07, 2022 11:25am
Starting run , today again 30-30% up?
At Nasdaq is up 9% already.
(264)
•••
moneywinner1
X
View Profile
View Bullboard History
Post by
moneywinner1
on Jun 07, 2022 10:27am
9% up on Nasdaq already
Starting to go up
(264)
•••
moneywinner1
X
View Profile
View Bullboard History
Comment by
moneywinner1
on Jun 07, 2022 10:23am
RE:RE:RE:RE:This news should have 50% gain
Look at Nasdaq is up 9% already this morning,
(2182)
•••
lscfa
X
View Profile
View Bullboard History
Comment by
lscfa
on Jun 07, 2022 9:27am
RE:Strong BUY initiated, now 1.80 target $17.50
It's a BS lie without a link. Alliance has a $11 cdn tp. https://europac.bluematrix.com/sellside/EmailDocViewer?encrypt=3d118b2d-89c3-40dc-b38e-8ba0270761f3&mime=pdf&co=Europac&id
...more
(264)
•••
moneywinner1
X
View Profile
View Bullboard History
Comment by
moneywinner1
on Jun 07, 2022 9:20am
RE:RE:RE:This news should have 50% gain
All shareholders were expecting this addition to the company . Now news on USA drug approval and this is going well into target . $17.50 USA
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >